IMRX 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-08-05

• In June 2026, we announced further positive interim response and safety data from the Phase 2 mGnP Arm. We announced that, as of a cutoff date of April 24, 2026 (the “Cutoff Date”), 17.3 month median overall survival (“mOS”) was observed in the intent-to-treat population of 55 patients dosed at the …

• available third-party MPACT pivotal trial data for gemcitabine/nab-paclitaxel. Our Phase 1/2a clinical trial of atebimetinib does not include a head-to-head comparison against any other agents, and caution should be exercised when comparing data across trials.

• We also announced that, as of the Cutoff Date, atebimetinib in combination with mGnP continued to be generally well tolerated. As of the Cutoff Date, Grade ≥ 3 treatment-emergent adverse events (“TEAEs”) observed in 10% or greater of patients in the 320 mg ITT Population consisted of Anemia (nine pa…

• •in the second half of 2026, dosing the first patient in a clinical trial of atebimetinib in combination with Libtayo® in non-small cell lung cancer patients, with a preliminary data readout expected in late-2027;

• •in the fourth quarter of 2026, additional pre-clinical data of atebimetinib in combination with anti-PD-1 in non-small cell lung cancer;

相对上期删除的文字 · 来源:10-Q · 2026-05-15

• We expect the following additional near-term milestones related to atebimetinib: announcing further updated survival and safety data from an expanded cohort of approximately 55 first-line pancreatic cancer patients treated with atebimetinib in combination with mGnP in our ongoing Phase 1/2a clinical…

• For the period from inception through 2017, we devoted substantially all of our efforts to business planning, service revenue generation, developing tools to aid in drug discovery, and recruiting management and technical staff. Since 2018,

• we have focused significant effort on our own internal research and development programs, and since December 2022 have exclusively focused our efforts on such programs. We have financed our operations through service revenues (which have since ceased), the issuance of convertible debt and the sale o…

• Based on our current business plans, we believe that our existing cash, cash equivalents and marketable securities as of March 31, 2026 will enable us to fund our development activities and other operations into 2029. We have based this

• estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. To finance our operations beyond that point we will need to raise additional capital, which cannot be assured. We may be unable to raise additional funds or enter into such…